Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  • Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
  • US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems
  • Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline

Holzkirchen, November 12, 2019 – Sandoz, a Novartis division and a global …

/by

New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis

  • 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1]
     
  • PREVENT is the largest ever study of a biologic in patients with nr-axSpA and underscores Novartis leadership in rheumatology[1]
     
  • There are approximately 1.7 million patients with nr-axSpA in the EU and US[2]
     
  • PREVENT adds to 5-year evidence in ankylosing spondylitis (AS) and is a step forward in providing patients with …
/by

Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  • Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
  • US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems
  • Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline

Holzkirchen, November 12, 2019 – Sandoz, a Novartis division and a global …

/by

Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  • Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
  • US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems
  • Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline

Holzkirchen, November 12, 2019 – Sandoz, a Novartis division and a global …

/by

Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market

  • Planned acquisition reinforces Sandoz strategic focus on Japan
  • Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands
  • Medicines complement Sandoz broad hospital portfolio and pipeline in Japan thereby expanding access to the hospital channel

Holzkirchen, Germany, November 11, 2019 – Sandoz today announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated …

/by

Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market

  • Planned acquisition reinforces Sandoz strategic focus on Japan
  • Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands
  • Medicines complement Sandoz broad hospital portfolio and pipeline in Japan thereby expanding access to the hospital channel

Holzkirchen, Germany, November 11, 2019 – Sandoz today announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated …

/by

Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar ZiextenzoTM (pegfilgrastim-bmez)

  • Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy
     
  • With approval of Ziextenzo™ , Sandoz is first and only company to offer US physicians long- and short-acting filgrastim biosimilar treatment options
     
  • With four US approved biosimilars, Sandoz is committed to expanding patient access, increasing healthcare savings and fueling innovation

Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global …

/by

Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar ZiextenzoTM (pegfilgrastim-bmez)

  • Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy
     
  • With approval of Ziextenzo™ , Sandoz is first and only company to offer US physicians long- and short-acting filgrastim biosimilar treatment options
     
  • With four US approved biosimilars, Sandoz is committed to expanding patient access, increasing healthcare savings and fueling innovation

Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global …

/by

Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US

  • Continuing operations2 net sales up 13% (cc1, +10% USD) driven by:
    • Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regions
    • Entresto USD 430 million (+61% cc), with increased demand in hospital and ambulatory settings
    • Zolgensma sales of USD 160 million, strong launch including broad access
    • Lutathera sales grew to USD 119 million, total AAA sales were USD 177 million
    • Piqray sales were USD 43 million, off to a strong start …
/by

Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine

  • Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS)
  • RRMS affects ~85% of MS patients and can create a substantial social and economic burden on patients, their families and healthcare systems[1],[2]
  • Natalizumab is fifth proposed biosimilar in-licensed by Sandoz in nine months, underscoring commitment to further grow pipeline through collaborations

Holzkirchen, Germany, September 3, 2019 …

/by